NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator
Email: TACommA@nice.org.uk
Fax: +44 (0)20 7061 9721
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by **Breast Cancer Care** and consequently I will not be submitting a personal statement.

Name: .....Tara Beaumont.....

Signed: .....

Date: .....30.05.13.....